About Prospect Venture Partners
Prospect Venture Partners is a venture capital firm founded in 1997. It is primarily based out of Palo Alto, United States. As of Oct 2016, Prospect Venture Partners has invested in 53 companies. It primarily invests in Series B round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and Enterprise Applications. Most recently it participated in the $***** Series D round of SentreHEART Overall, Prospect Venture Partners portfolio has seen 7 IPOs and 28 acquisitions including key companies like Jazz Pharmaceuticals, Insmed and Complete Genomics. A lot of funds co-invest with Prospect Venture Partners, with names like Rho Capital Partners sharing a substantial percentage of its portfolio. Prospect Venture Partners has team of 3 people including 3 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series B, Series A & 3 more
Portfolio IPOs
Portfolio Acquisitions
Portfolio Soonicorns
Prospect Venture Partners' List of Top Investments
Prospect Venture Partners has a portfolio of 53 companies. Their most notable investments are in Complete Genomics and Pathwork Diagnostics.Their portfolio spans across United States, Belgium, China and 1 more locations. They have invested in Life Sciences, High Tech, Enterprise Applications and 9 other sectors, across stages such as Series B, Series A and 3 more. Here is the list of top investments by Prospect Venture Partners:
Developer of novel biopharmaceutical medicines for unmet medical needs. It focuses on developing and delivering life-changing medications to patients with limited or no treatment options. The company's pipeline includes various therapeutic areas, and it supports its medicines with robust clinical trial programs and patient support resources. Research efforts prioritize patient needs, driving advancements in understanding and treating specific conditions. The company also engages in corporate giving and sustainability initiatives.
Key facts about Jazz Pharmaceuticals
- Founded Year: 2003
- Location: Dublin (Ireland)
- Annual Revenue: $500M - $1B as on Dec 31, 2020
- Stage: Public
- Total Funding till date: $265M
- Employee Count: 3,648 as on Jul 31, 2026
- Investors: Adams Street Partners, Thoma Bravo and 14 Others
- Latest Funding Round: Post IPO, Jul 07, 2009, $*****
- Highlight: Public
2. Insmed
Developer of small molecule inhibitors for rare lung diseases. Its lead candidate is Arikayce (liposomal amikacin for inhalation), a ribosomal 30S subunit inhibitor for nontuberculous mycobacteria (NTM) lung disease. It also has an earlier-stage clinical pipeline which includes INS1009, a nebulized prodrug formulation of treprostinil that claims to have potential in rare pulmonary disorders such as pulmonary arterial hypertension (PAH), idiopathic pulmonary fibrosis (IPF) sarcoidosis, and severe refractory asthma.
Key facts about Insmed
- Founded Year: 1999
- Location: Bridgewater (United States)
- Annual Revenue: $500M - $1B as on Dec 31, 2025
- Stage: Public
- Employee Count: 1,765 as on Jul 31, 2026
- Investors: Foresite Capital, Quaker Partners Management and 13 Others
- Latest Funding Round: Grant (prize money), Apr 29, 2025, $*****
- Highlight: Public
Complete Genomics is a developer of DNA sequencing platform for human genome sequencing and analysis. It has developed a DNA sequencing platform based on its proprietary DNA nanoball sequencing technology. It is a method of rolling cycle replication to clonally amplify small fragments of DNA into DNA nanoballs which are then attached to a microarray flow cell and sequenced. The sequencing generates fragment lengths of 250-500 bp (mate pair distance), which can then be analyzed using proprietary algorithms. The company's platform is called the Revolocity Platform and is optimized for the Human whole genome and whole exome sequencing. The company also provides analysis and data management software for generating finished variant reports and assemblies.
Key facts about Complete Genomics
- Founded Year: 2006
- Location: San Jose (United States)
- Annual Revenue: $10M - $50M as on Dec 31, 2011
- Stage: Acquired
- Total Funding till date: $125M
- Employee Count: 240 as on Jul 31, 2026
- Investors: Enterprise Partners Venture Capital, Orbimed and 8 Others
- Latest Funding Round: Series E, Aug 19, 2010, $*****
- Highlight: Acquired
4. Nanosys
Developer of nanotechnology-based displays. It provides quantum dots and nanometer-sized crystals for creating LED display systems. It is more energy-efficient, more responsive, and brighter than traditional display technology.
Key facts about Nanosys
- Founded Year: 2001
- Location: Milpitas (United States)
- Stage: Acquired
- Total Funding till date: $267M
- Employee Count: 111 as on May 31, 2026
- Investors: Archer Venture Capital, Medtronic and 30 Others
- Latest Funding Round: Series F, Jul 25, 2022, $*****
- Highlight: Acquired
5. Novavax
Developer of novel vaccines for the treatment of infectious diseases. Its pipeline includes a vaccine for respiratory syncytial virus infection, coronavirus, malaria, ebola, and seasonal quadrivalent vaccines for influenza. It uses recombinant nanoparticles and adjuvant technology.
Key facts about Novavax
- Founded Year: 1987
- Location: Gaithersburg (United States)
- Annual Revenue: $1B+ as on Dec 31, 2025
- Stage: Public
- Employee Count: 951 as on Jul 31, 2026
- Investors: Foresite Capital, RA Capital Management and 13 Others
- Latest Funding Round: Post IPO, Sep 08, 2023, $*****
- Highlight: Public
Prospect Venture Partners' Investments by Stage
Prospect Venture Partners has made 18 investments in Series B stage with an average round size of $28.4M, 12 investments in Series A stage with an average round size of $25.1M, 7 investments in Series C stage with an average round size of $29.4M, 2 investments in Series D stage with an average round size of $31.1M and 1 investment in PE stage with an average round size of $200M.Stage of entry | No. of Investments |
|---|---|
Series B | 18 |
Series A | 12 |
Series C | 7 |
Series D | 2 |
PE | 1 |
Note: We have considered here, only first round of investments
Prospect Venture Partners' Investments by Sector
Prospect Venture Partners has a diverse portfolio, with companies operating in the Life Sciences, High Tech, Consumer, Sustainability Tech and Healthcare. Notably, it has invested in 42 Tech companies, 33 Enterprise (B2B) companies, 11 Software companies and at least 9 companies focusing on Consumer (B2C).Sector | No. of Investments |
|---|---|
Life Sciences | 34 |
High Tech | 4 |
Consumer | 3 |
Sustainability Tech | 3 |
Healthcare | 2 |
Others | 7 |
Note: We have considered here, only first round of investments
Prospect Venture Partners' Investments by Geography
Prospect Venture Partners has made most investments in United States (37), followed by Belgium where it has made 1 investment.Country | No. of Investments |
|---|---|
United States | 37 |
Belgium | 1 |
China | 1 |
Ireland | 1 |
Note: We have considered here, only first round of investments
Prospect Venture Partners' recent investments
Prospect Venture Partners has not made any investment in 2026 so far.Here are the most recent investments by Prospect Venture Partners:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Oct 14, 2016 | United States | Series D | 6730 | [+3] | |
Feb 23, 2015 | United States | Series D | 3019 | [+2] | |
Apr 22, 2014 | United States | Series B | 3048 | [+3] | |
Mar 18, 2014 | United States | Series B | 2422 | [+1] | |
Jul 18, 2013 | United States | Series C | 4266 | [+1] |
IPOs and Publicly Listed companies in Prospect Venture Partners' Portfolio
7 of Prospect Venture Partners' portfolio companies have become public. Idun Pharmaceuticals got listed on the Stockholm Stock Exchange (STO), in Mar 2021 and NGM Biopharmaceuticals got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ) at marketcap of $1.04B.Here are Prospect Venture Partners' portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Mar 26, 2021 | Jun 14, 2004 | Series B | 8440 | |
Apr 05, 2019 | Feb 11, 2008 | Series A | 6762 | |
Jun 01, 2007 | Apr 2003 | Series A | 1076 | |
Apr 12, 2006 | Oct 2004 | Series B | 4196 | |
Jul 28, 2000 | - | - | 1698 |
Acquired companies in Prospect Venture Partners' Portfolio
28 companies from Prospect Venture Partners' portfolio have been acquired. The most recent acquisition was Complete Genomics in Feb 2026 by Swiss Rockets for $*****.Here are Prospect Venture Partners' portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Feb 23, 2026 | Mar 31, 2008 | Series C | 4075 | |
Dec 19, 2025 | May 12, 2004 | Series B | 6795 | |
Oct 18, 2022 | Oct 2003 | Series B | 7934 | |
Oct 18, 2022 | Feb 15, 2002 | Series B | 9187 | |
May 05, 2020 | Dec 08, 2003 | Series A | 7893 |
Team profile of Prospect Venture Partners
Prospect Venture Partners has a team of 3 members including 3 Partners located in United States. Prospect Venture Partners' team does not sit on the board of any company as of now.Here is a list of all team members in Prospect Venture Partners:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Palo Alto | - | - | |
Partner | Atlantic City | - | - | |
Partner | United States | - | - |
Co-investors of Prospect Venture Partners
Over the past 24 years, 203 investors have co-invested in Prospect Venture Partners's portfolio companies. This includes only funds.
- Invested before Prospect Venture Partners: Arch Venture Partners, Venrock and 27 others have invested in rounds before Prospect Venture Partners. There are 3 companies where Arch Venture Partners has invested before Prospect Venture Partners and 2 companies where Venrock has invested before Prospect Venture Partners.
- Top Co-investors of Prospect Venture Partners: 77 investors entered a company along with Prospect Venture Partners. These include investors like Rho Capital Partners (5 companies).
- Invested after Prospect Venture Partners: A total of 97 investors have invested in Prospect Venture Partners's portfolio after their investments. Top Investors include Orbimed (2 companies), HBM Healthcare Investments (2 companies) and New Enterprise Associates (2 companies).
Recent News related to Prospect Venture Partners
•
Alvinepharma.comAlvine Pharma•Jun 26, 2018•Alvine Pharma, Panorama Capital, InterWest Partners, Prospect Venture Partners and 3 others
•
032315 | Press Releases | NGM BioNGM Biopharmaceuticals•Mar 23, 2015•NGM Biopharmaceuticals, Prospect Venture Partners, The Column Group, Topspin Consumer Partners
•
•
NinePoint Medical Completes $34M Series BMassinvestor•Mar 20, 2014•NinePoint Medical, Third Rock Ventures, Prospect Venture Partners, Corning
•
071813 | Press Releases | NGM BioNGM Biopharmaceuticals•Jul 18, 2013•NGM Biopharmaceuticals, Topspin Consumer Partners, Prospect Venture Partners, Rho Ventures
•
•
DFINE, Inc. Announces Close of $25 Million Financing | Business WireBusiness Wire•Nov 08, 2011•DFine, Orbimed, Prospect Venture Partners, Split Rock Partners and 3 others
•
•
•
